Summary of the details of postacute iNO administration in preterm infants in the included studies
| Author year | Postnatal day of iNO initiation | Dosage of iNO (ppm) | Duration of iNO | Other drugs | Discontinuation criteria | Adverse effects | |
| 1 | Ballard et al, 20068 | 7–21 days | Start with 20 ppm for 48–96 hours Decreased to 10, 5, and 2 ppm at weekly intervals | Minimum 24 days | N/A | Specified by the protocol | No difference in the complications of prematurity No methaemoglobinaemia |
| 2 | Ballard et al, 201611 | 7–14 days | Start with 20 ppm for 48–96 hours Decreased to 10, 5, and 2 ppm at weekly intervals | Minimum 24 days | Surfactant | Specified by the protocol | No difference in severe adverse events and complications of prematurity |
| 3 | Hasan et al, 20179 | 7–14 days | Start with 20 ppm Decreased to 10 ppm in 72–96 hours Then 5 ppm on day 10 or 11 Remain at 5 ppm until completion of therapy for 24 days | Minimum 24 days | N/A | Specified by the protocol | No differences in common complications of prematurity No elevation in NO2 or methaemoglobin level |
| 4 | Truog et al, 201410 | 7–28 days: (n=140 or 2.9%) >28 days: (n=47 or 0.96%) | N/A | N/A | N/A | N/A | N/A |
| 5 | Hsiao et al, 201920 | >7 days | Start with 20 ppm (rarely 10 ppm) Increased to 40 ppm without clinical response (max 80 ppm) | N/A | Surfactant 1/27 (3.7%) Dopamine 10/27 (37.0%) Dobutamine 6/27 (22.2%) Epinephrine 3/27 (11.1%) Milrinone 6/27 (22.2%) | N/A | N/A |
| 6 | Nakanishi et al, 20234 | N/A (postacute iNO; defined as iNO administration in the late phase of hospitalisation) | N/A | 26 days (14–70 days) | N/A | N/A | N/A |
| 7 | Oka et al, 202313 | 19 (11–26) days | Starting dose: 10 ppm | 20.5 (8–32.5) days | Surfactant corticosteroid | N/A | No complications No methaemoglobinaemia |
| 8 | Fraga et al, 202314 | 40 weeks (37–43) | 20 ppm | N/A | Bronchodilators; n=16 (43%) Diuretics; furosemide: n=15 (40%), chlorothiazide: n=16 (43%) | N/A | Pulmonary oedema; n=1 |
| 9 | Nakao et al, 201222 | >7 days (214–2880 hours) | Starting dose: 3–20 ppm Highest dose: 5–40 ppm | Median 130 hours (22–1330 hours) | N/A | N/A | No complications |
| 10 | Iwatani et al, 202221 | 39 (12–142) days | N/A | 2–36 days | N/A | N/A | No methaemoglobinaemia No jaundice |
iNO, inhaled nitric oxide; ppm, parts per million.